• As the name implies, macromolecular drugs refer to those drugs with large molecular weight. They use biotechnology to make products from microorganisms, plants and animal cells to treat diseases derived from the lack of such proteins in the body. They are also called Biologics and protein drug. Biologics are less likely to cause systemic toxicity due to their uniqueness and specificity. At present, they are widely used in the treatment of anemia, cancer, autoimmune diseases and the like, which is a good news for a new generation of patients. Due to technical difficulties in production, the price of macromolecular drugs is about twenty times that of traditional chemotherapeutic drugs. Compared to the serious side effects caused by traditional chemotherapy, the potency of the monoclonal antibody is low and the side effects are low. However, on the average, the annual price of mAb therapies is about $100,000.
• The mature markets such as the United States, Europe and Japan are the main markets for biologics, accounting for 81% of the total. With the improvement of economy in emerging countries and the emphasis on biotechnology, biopharmaceuticals will grow rapidly in emerging countries in the future.
• At present, the total market value of monoclonal antibody-related drugs is about 65.5 billion U.S. dollars (accounting for 40% of the total biological agents). In recent years, the market growth rate has been maintained at about 10%. At the end of 2014, of the top 10 best-selling drugs in the world, 7 were single Antibody drugs, if not for the treatment of hepatitis C small molecule drugs in the past two years suddenly emerged, it is generally estimated that in 2016 the top 10 best-selling drugs will be the world's monoclonal antibody. 

REFERENCE